Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

India considers resuming vaccine exports soon, focus on Africa, says source

Published 09/15/2021, 03:14 AM
Updated 09/15/2021, 03:16 AM
© Reuters. FILE PHOTO: A man displays a vial AstraZeneca's COVISHIELD vaccine as the country receives its first batch of coronavirus disease (COVID-19) vaccines under COVAX scheme, in Accra, Ghana February 24, 2021. REUTERS/Francis Kokoroko/File Photo

By Krishna N. Das

NEW DELHI (Reuters) - India is considering resuming exports of COVID-19 vaccines soon, mainly to Africa, as it has partly immunised a majority of its adults and supplies have surged, a source with knowledge of the matter told Reuters.

India, the world's biggest maker of vaccines overall, stopped vaccine exports in April to focus on inoculating its own population as infections exploded.

The government wants to vaccinate all of its 944 million adults by December and has so far given at least one dose to 61% of them.

The resumption of exports deliberations come ahead of Prime Minister Narendra Modi's visit to Washington https://www.reuters.com/world/biden-host-leaders-australia-japan-india-sept-24-white-house-2021-09-13 next week where vaccines are likely to be discussed at a summit of the leaders of the Quad countries - the United States, India, Japan and Australia.

"The export decision is a done deal," said the source, who declined to be named as he was not authorised to talk to the media on the matter. "India wants to help out Africa with both vaccines and its COVID operational model."

India's Ministry of External Affairs, one of whose senior officials met with the chief of the World Health Organization https://twitter.com/DrTedros/status/1437407259819130885 on Monday, did not immediately respond to a request for comment. The ministry coordinates India's vaccine exports.

The WHO said on Tuesday it was in a constant dialogue with Indian officials to resume supplies to global vaccine-sharing platform COVAX.

"We have been assured that supply will restart this year," senior WHO official Bruce Aylward said https://www.who.int/multi-media/details/who-press-conference-on-coronavirus-disease-(covid-19)---14-september-2021# in a briefing.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"We are hoping we can get an assurance it can start even faster than later this year, and in the coming weeks."

Before India stopped exports, it donated or sold 66 million doses to nearly 100 countries.

India's own inoculations have jumped since last month, especially as the world's biggest vaccine maker, the Serum Institute of India, has more than doubled its output https://www.reuters.com/world/india/indias-covid-vaccine-supply-jumps-raising-export-hopes-2021-08-30 of the AstraZeneca (NASDAQ:AZN) shot to 150 million doses a month from its April levels.

A government source told Reuters in June that the U.S. experience showed that vaccinations tend to slow down after a big majority of people get their shots. That might give India a chance to export excess output, said the source.

The African Union on Tuesday accused manufacturers of denying them a fair chance to buy vaccines, and urged manufacturing countries - in particular India - to lift export restrictions.

Out of 5.7 billion doses of coronavirus vaccines administered around the world, only 2% have been in Africa https://www.reuters.com/article/health-coronavirus-who/update-1-african-union-slams-vaccine-manufacturers-for-restricting-access-idINL8N2QG4CK.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.